This website is intended for healthcare professionals only.

Newsletter          
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Oncology

Patients with advanced mCRC have a new treatment option as LONSURF® receives EU approval
Patients with advanced mCRC have a new treatment option as LONSURF® receives EU approval
EADV launches Global Call to Action to protect outdoor workers from skin cancer caused by the sun
EADV launches Global Call to Action to protect outdoor workers from skin cancer caused by the sun
Selvita files IND application for its novel, dual PIM/FLT3 inhibitor in AML
Selvita files IND application for its novel, dual PIM/FLT3 inhibitor in AML
Merck and Sysmex Inostics receive CE Mark approval for liquid biopsy test for colorectal cancer
Merck and Sysmex Inostics receive CE Mark approval for liquid biopsy test for colorectal cancer
CHMP issues a positive opinion on Janssen’s single-agent Darzalex® (daratumumab)
CHMP issues a positive opinion on Janssen’s single-agent Darzalex® (daratumumab)
Survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone
Survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone
Spectrila® (asparaginase) by Medac received EU-wide approval for the treatment of ALL
Spectrila® (asparaginase) by Medac received EU-wide approval for the treatment of ALL
LC Bead LUMI™ Radiopaque Embolic Bead supported by Philips Live Image Guidance
LC Bead LUMI™ Radiopaque Embolic Bead supported by Philips Live Image Guidance
Keytruda® significantly improves survival compared with chemotherapy in NSCLC
Keytruda® significantly improves survival compared with chemotherapy in NSCLC
Proton Partners International bring top cancer technology to Wales
Proton Partners International bring top cancer technology to Wales
Advances in cancer diagnosis by Coventry scientists
Advances in cancer diagnosis by Coventry scientists
Takeda presents data from Phase III TOURMALINE-MM1 study for NINLARO®
Takeda presents data from Phase III TOURMALINE-MM1 study for NINLARO®


Popular articles

Study shows HIV vaccine ineffective
RSV vaccine meets primary endpoint in older adults
Yescarta approved by NICE for relapsed/remitted lymphomas
Single low-dose CT scan helps predict future lung cancer risk
Dupixent approved for severe atopic dermatitis in children from 6 months




 

Download Hospital Healthcare Europe free app

Download our app from the Apple App Store Download our app from Google Play

In official association with

HOPE Logo Footer

© Cogora 2023
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora